Trial
NCT01931566
Biomarker Qualification for Risk of Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease (AD) and Safety and Efficacy Evaluation of Pioglitazone in Delaying Its Onset
Phase IIITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
Takeda
Collaborators
Zinfandel Pharmaceuticals Inc.
Condition
Mild Cognitive Impairment Due to Alzheimer's Disease
Intervention
Pioglitazone
Why stopped
Lack of efficacy of the drug; no safety concern
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2019-09-16